Belgian biopharmaceuticals company UCB has agreed to buy privately-held Candid Therapeutics in a deal worth up to $2.2 billion, the companies said on Sunday. UCB will pay $2 billion in upfront...
Belgian pharma group UCB to buy Candid Therapeutics for up to $2.2 billion
